Biocon Limited - Company Snapshot & SWOT Analysis
From being an enzyme venture, Biocon successfully emerged as a biotechnology company in less than two decades time and now is a fully-integrated Biopharmaceutical company. The parent company’s key subsidiaries are Syngene International Limited, Biocon Biopharmaceuticals Private Limited, Biocon Research Limited, Switzerland-based Biocon SA and Malaysia-based Biocon SDN.BHD. Also, The Company owns 50% stake in Abu Dhabi-based NeoBiocon FZ.
Biocon Limited revenue has grown from INR 25.38 bn to INR 43.36 bn during 2013-2018. The company is showing an annual growth rate of 11.31%. During the same period about 63% of the revenues in FY 2018 was from overseas market. Domestic market contributed to 37% of the total revenues.
Scope of the Biocon Limited - Company Snapshot & SWOT Analysis Report
Biocon Limited revenue has grown from INR 25.38 bn to INR 43.36 bn during 2013-2018. The company is showing an annual growth rate of 11.31%. During the same period about 63% of the revenues in FY 2018 was from overseas market. Domestic market contributed to 37% of the total revenues.
Scope of the Biocon Limited - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Biocon Limited including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Biocon Limited - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Biocon Limited
3.1.1 Company Profile
3.1.2 Biocon Limited in Pharmaceutical Manufacturing Value Chain
3.1.3 Biocon Limited: Financial Performance
3.1.4 Biocon Limited: Business Strategy
3.1.4.1 Product Level Business Strategy
3.1.4.2 Service Level Business Strategy
3.1.5 SWOT Analysis of Biocon Limited
Strengths
Weaknesses
Opportunities
Threats
3.1.6 Key Customers of Biocon Limited
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
Scope of the Biocon Limited - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Biocon Limited
3.1.1 Company Profile
3.1.2 Biocon Limited in Pharmaceutical Manufacturing Value Chain
3.1.3 Biocon Limited: Financial Performance
3.1.4 Biocon Limited: Business Strategy
3.1.4.1 Product Level Business Strategy
3.1.4.2 Service Level Business Strategy
3.1.5 SWOT Analysis of Biocon Limited
Strengths
Weaknesses
Opportunities
Threats
3.1.6 Key Customers of Biocon Limited
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Biocon Limited
Exhibit 3.2 Contact Information of Biocon Limited
Exhibit 3.3 Biocon Ltd in Pharma Manufacturing Value Chain
Exhibit 3.4 Biocon Limited Revenue 2013-2018 (in INR billion)
Exhibit 3.5 Year-wise Biocon Limited Revenue Growth 2013-18 (in %)
Exhibit 3.6 Category Wise Revenue Breakup for Biocon Limited 2018 (in INR billion)
Exhibit 3.7 Estimated Year wise Biocon Limited Revenue 2019-2023 (in INR billion)
Exhibit 3.8 Key Products of Biocon Limited
Exhibit 3.9 Key Services Offered by Biocon Limited
Exhibit 3.10 SWOT Analysis of Biocon Limited
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Biocon Limited
Exhibit 3.2 Contact Information of Biocon Limited
Exhibit 3.3 Biocon Ltd in Pharma Manufacturing Value Chain
Exhibit 3.4 Biocon Limited Revenue 2013-2018 (in INR billion)
Exhibit 3.5 Year-wise Biocon Limited Revenue Growth 2013-18 (in %)
Exhibit 3.6 Category Wise Revenue Breakup for Biocon Limited 2018 (in INR billion)
Exhibit 3.7 Estimated Year wise Biocon Limited Revenue 2019-2023 (in INR billion)
Exhibit 3.8 Key Products of Biocon Limited
Exhibit 3.9 Key Services Offered by Biocon Limited
Exhibit 3.10 SWOT Analysis of Biocon Limited
